Alzheimer’s Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2020–2027
A10535 | Pages: NA | Jun 2021 | 59 Views | | |
Author(s) : NA | Tables: NA | Charts: NA | Formats*: | |
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Alzheimer’s Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2020–2027
Request Now !Alzheimer's disease is a progressive disorder that causes brain cells to degenerate and die. It is the most common cause of dementia, a continuous decline in thinking, behavioral, and social skills that disrupts a person's ability to function independently. The early signs of the disease include forgetting recent events or conversations. As the disease progresses, a person develops severe memory impairment and loses the ability to carry out everyday tasks. Current Alzheimer's disease medications may temporarily improve symptoms or slow the rate of decline. These treatments can sometimes help people with Alzheimer's to maximize function and maintain independence for a certain time. Different programs and services can help support people with Alzheimer's disease and their caregivers.
Market scope and structure analysis :
Report Metric | Details |
Market size available for years | 2020–2027 |
Base year considered | 2020 |
Forecast period | 2021–2027 |
Forecast units | Value (USD) |
Segments covered | Drug Class, distribution channel and Region |
Regions covered | North America (U.S. and Canada), Europe (Germany, UK, France, and Rest of Europe), Asia Pacific (China, Japan, India, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of LATAM) and Middle East and Africa |
Companies covered | Major players analyzed include Pfizer, Inc., Merck & Co. Inc., Novartis AG, Eisai Co. Ltd., H. Lundbeck A/S, AC Immune, TauRx Pharmaceuticals Ltd., Actavis plc., Forest Laboratories, Teva Pharmaceuticals Industries Ltd., Janssen Pharmaceutical, GE healthcare, Eli Lilly and Company, DiaGenic ASA, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca, and Daiichi Sankyo Company Ltd. |
COVID-19 scenario analysis:
Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.
Top impacting factors: Market Scenario Analysis, Trends, Drivers, and Impact Analysis
Surge in number of incidences of Alzheimer’s disease would help the industry propel during the forecast period. Rise in prevalence of geriatric population is expected to boost the Alzheimer’s therapeutics market in coming years. In addition, se in awareness among population regarding the symptoms caused due to the diseases is projected to propel the Alzheimer’s therapeutics market growth.
Growth in the number of product launches to boost the market
Growth in number of product launches is expected to help the industry flourish during the forecast period. For instance, in February 2020, Biogen prepared to step up manufacturing to support Alzheimer’s launch.
Furthermore, in June 2020, Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for management of central nervous system (CNS) disorders, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for AXS-05 for the treatment of Alzheimer’s disease (AD). AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. This is the second breakthrough therapy designation granted to Axsome for AXS-05. There is currently no approved treatment for AD agitation.
Surge in number of mergers and acquisitions to propel the market
Increase in number of mergers and acquisitions is anticipated to help the industry grow in the coming years. For instance, in December 2020, Eli Lilly joined ranks of big pharmaceutical companies, by building a position in gene therapy. It paid about $26.50 per share to acquire New York-based Prevail Therapeutics. Furthermore, it acquired Prevail Therapeutics’ two clinical-stage development programs. Prevail Therapeutics has several gene therapies in preclinical testing, which include candidates for a group of neurodegenerative conditions. The conditions include synucleinopathies, as well as Alzheimer's disease and even amyotrophic lateral sclerosis.
Key segments covered:
Segments | Subsegments |
Drug Class |
|
Distribution Channel |
|
Key benefits of the report:
- This study presents the analytical depiction of the global Alzheimer’s therapeutics industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Alzheimer’s therapeutics market share.
- The current market is quantitatively analyzed from 2020 to 2027 to highlight the global Alzheimer’s therapeutics market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the Alzheimer’s therapeutics market.
- The report provides a detailed global Alzheimer’s therapeutics market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Alzheimer’s therapeutics Market research report:
- Which are the leading market players active in the Alzheimer’s therapeutics market?
- What would be the detailed impact of COVID-19 on the Alzheimer’s therapeutics market??
- What current trends would influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the Alzheimer’s therapeutics market?
- What are the projections for the future that would help in taking further strategic steps?
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
Access from any device, anywhere
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
REQUEST TOC/SAMPLE
Purchase Full Report of
Alzheimer’s Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2020–2027
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Single User
-
$5,769$5,192 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Library Membership
- $ 699/mo
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Featured Reports
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers